The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
|Videos|April 13, 2018
EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases
EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases
Advertisement
June 2017
- A 61-year-old Caucasian woman presented with persistent cough and shortness of breath
- Patient history:
- Never smoked
- Mild hypertension, controlled on diuretic
- No major cardiovascular disease or diabetes
- Worked at local jazz club until symptoms forced her to resign
- Physical exam and imaging:
- No palpable masses
- CT reveals multiple tumors in right lung and brain metastases
- ECOG PS: 1
- Biopsy and mutation analysis:
- Adenocarcinoma
- EGFRexon 19 deletion
- No ALK rearrangement
- Started treatment with afatinib 40 mg once daily
- Developed diarrhea that necessitated dose interruption
- Recovered and resumed treatment at 30 mg once daily
March 2018
- Patient remains on afatinib, with no apparent progression
Advertisement
Related to this article
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
3
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
4
IMS 2026 Day 3 Recap: Etentamig Outperforms Standard Therapy in RRMM Trial
5